JP2021505526A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021505526A5 JP2021505526A5 JP2020521320A JP2020521320A JP2021505526A5 JP 2021505526 A5 JP2021505526 A5 JP 2021505526A5 JP 2020521320 A JP2020521320 A JP 2020521320A JP 2020521320 A JP2020521320 A JP 2020521320A JP 2021505526 A5 JP2021505526 A5 JP 2021505526A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- use according
- inhibitor
- combination
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023082991A JP2023109899A (ja) | 2017-10-31 | 2023-05-19 | 少なくとも１つのスプライソソームモジュレーターと、ｂｃｌ２阻害剤、ｂｃｌ２／ｂｃｌｘｌ阻害剤及びｂｃｌｘｌ阻害剤から選択される少なくとも１つの阻害剤とを含む組合せ、並びに使用の方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762579666P | 2017-10-31 | 2017-10-31 | |
| US62/579,666 | 2017-10-31 | ||
| US201762580364P | 2017-11-01 | 2017-11-01 | |
| US62/580,364 | 2017-11-01 | ||
| PCT/US2018/058277 WO2019089641A1 (en) | 2017-10-31 | 2018-10-30 | Combination comprising at least one spliceosome modulator and at least one inhibitor chosen from bcl2 inhibitors, bcl2/bclxl inhibitors, and bclxl inhibitors and methods of use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023082991A Division JP2023109899A (ja) | 2017-10-31 | 2023-05-19 | 少なくとも１つのスプライソソームモジュレーターと、ｂｃｌ２阻害剤、ｂｃｌ２／ｂｃｌｘｌ阻害剤及びｂｃｌｘｌ阻害剤から選択される少なくとも１つの阻害剤とを含む組合せ、並びに使用の方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021505526A JP2021505526A (ja) | 2021-02-18 |
| JP2021505526A5 true JP2021505526A5 (https=) | 2021-12-02 |
Family
ID=64277937
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020521320A Pending JP2021505526A (ja) | 2017-10-31 | 2018-10-30 | 少なくとも１つのスプライソソームモジュレーターと、ｂｃｌ２阻害剤、ｂｃｌ２／ｂｃｌｘｌ阻害剤及びｂｃｌｘｌ阻害剤から選択される少なくとも１つの阻害剤とを含む組合せ、並びに使用の方法 |
| JP2023082991A Pending JP2023109899A (ja) | 2017-10-31 | 2023-05-19 | 少なくとも１つのスプライソソームモジュレーターと、ｂｃｌ２阻害剤、ｂｃｌ２／ｂｃｌｘｌ阻害剤及びｂｃｌｘｌ阻害剤から選択される少なくとも１つの阻害剤とを含む組合せ、並びに使用の方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023082991A Pending JP2023109899A (ja) | 2017-10-31 | 2023-05-19 | 少なくとも１つのスプライソソームモジュレーターと、ｂｃｌ２阻害剤、ｂｃｌ２／ｂｃｌｘｌ阻害剤及びｂｃｌｘｌ阻害剤から選択される少なくとも１つの阻害剤とを含む組合せ、並びに使用の方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11524009B2 (https=) |
| EP (1) | EP3703755B1 (https=) |
| JP (2) | JP2021505526A (https=) |
| KR (1) | KR20200083532A (https=) |
| CN (1) | CN111727059A (https=) |
| AU (1) | AU2018360559B2 (https=) |
| BR (1) | BR112020008362A2 (https=) |
| CA (1) | CA3079089A1 (https=) |
| IL (1) | IL274150A (https=) |
| MX (1) | MX2020004179A (https=) |
| SG (1) | SG11202003197TA (https=) |
| WO (1) | WO2019089641A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI721623B (zh) | 2018-10-31 | 2021-03-11 | 美商基利科學股份有限公司 | 經取代之6-氮雜苯并咪唑化合物 |
| TW202136261A (zh) | 2018-10-31 | 2021-10-01 | 美商基利科學股份有限公司 | 經取代之6-氮雜苯并咪唑化合物 |
| US11453681B2 (en) | 2019-05-23 | 2022-09-27 | Gilead Sciences, Inc. | Substituted eneoxindoles and uses thereof |
| EP4051286A1 (en) * | 2019-10-29 | 2022-09-07 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods and compositions for treating uveal melanoma |
| AR122546A1 (es) * | 2020-06-05 | 2022-09-21 | Eisai R&D Man Co Ltd | Conjugados de anticuerpo anti bcma-fármaco y métodos de uso |
| ES2919898B8 (es) * | 2021-01-27 | 2024-02-02 | Fundacion Univ San Antonio | Nuevo tratamiento del cáncer colorrectal |
| CN112691195B (zh) * | 2021-02-02 | 2023-03-14 | 黑龙江省科学院高技术研究院 | Prpf8表达抑制剂在制备治疗肺癌的药物中的应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI311558B (en) | 2001-02-01 | 2009-07-01 | Mercian Corporatio | Novel physiologically active substance |
| JP4459051B2 (ja) | 2002-07-31 | 2010-04-28 | メルシャン株式会社 | 新規生理活性物質 |
| RU2338741C2 (ru) | 2002-07-31 | 2008-11-20 | Мершан Корпорейшн | Новые физиологически активные вещества |
| WO2004037212A2 (en) | 2002-10-24 | 2004-05-06 | Sepracor, Inc. | Compositions comprising zopiclone derivatives and methods of making and using the same |
| JP4439401B2 (ja) | 2002-11-29 | 2010-03-24 | メルシャン株式会社 | マクロライド系化合物の製造方法 |
| EP1705247A4 (en) | 2003-11-27 | 2008-08-20 | Mercian Corp | DNA ACCOMPANYING HYDROXYLATION OF A MAKROLIDE COMPOUND |
| CN1977046A (zh) | 2004-07-20 | 2007-06-06 | 卫材R&D管理有限公司 | 编码参与普拉地内酯生物合成的多肽的dna |
| EP1792622A1 (en) * | 2005-11-11 | 2007-06-06 | GPC Biotech AG | Anti-proliferative combination therapy comprising a platinum-based chemotherapeutic agent and EGFR inhibitors or pyrimidine analogues |
| US20080312317A1 (en) | 2007-04-12 | 2008-12-18 | Eisai R&D Management Co., Ltd. | 12 membered-ring macrolactam derivatives |
| AU2009279936A1 (en) * | 2008-08-05 | 2010-02-11 | Banyu Pharmaceutical Co., Ltd. | Therapeutic compounds |
| US8211928B2 (en) | 2009-05-29 | 2012-07-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2014089571A1 (en) * | 2012-12-09 | 2014-06-12 | St. Jude Children's Research Hospital | Anticancer compounds |
| EP2934531A4 (en) * | 2012-12-19 | 2016-06-15 | Glaxosmithkline Llc | COMBINATION |
| PE20160671A1 (es) | 2013-08-02 | 2016-07-09 | Pfizer | Anticuerpos anti-cxcr4 y conjugados de anticuerpo y farmaco |
| UA119458C2 (uk) * | 2014-05-15 | 2019-06-25 | Ейсей Р Енд Д Менеджмент Ко., Лтд. | Сполуки піридину пладієноліду та способи застосування |
| RU2726367C2 (ru) * | 2016-03-28 | 2020-07-13 | Пресидж Байосайенсиз, Инк. | Фармацевтические комбинации для лечения злокачественной опухоли |
-
2018
- 2018-10-30 SG SG11202003197TA patent/SG11202003197TA/en unknown
- 2018-10-30 BR BR112020008362-3A patent/BR112020008362A2/pt not_active IP Right Cessation
- 2018-10-30 JP JP2020521320A patent/JP2021505526A/ja active Pending
- 2018-10-30 AU AU2018360559A patent/AU2018360559B2/en not_active Expired - Fee Related
- 2018-10-30 CN CN201880070827.6A patent/CN111727059A/zh active Pending
- 2018-10-30 EP EP18801253.8A patent/EP3703755B1/en active Active
- 2018-10-30 CA CA3079089A patent/CA3079089A1/en active Pending
- 2018-10-30 WO PCT/US2018/058277 patent/WO2019089641A1/en not_active Ceased
- 2018-10-30 KR KR1020207015324A patent/KR20200083532A/ko active Pending
- 2018-10-30 MX MX2020004179A patent/MX2020004179A/es unknown
- 2018-10-30 US US16/760,313 patent/US11524009B2/en active Active
-
2020
- 2020-04-22 IL IL274150A patent/IL274150A/en unknown
-
2023
- 2023-05-19 JP JP2023082991A patent/JP2023109899A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021505526A5 (https=) | ||
| Seo et al. | The role of epithelial–mesenchymal transition-regulating transcription factors in anti-cancer drug resistance | |
| ES2655443T7 (es) | Compuestos antagonistas de E-selectina | |
| CN113767106A (zh) | 氧杂氮杂喹唑啉-7(8h)-酮类化合物,其制法与医药上的用途 | |
| CY1118191T1 (el) | Αναλογα δεοξυνοζιριμυκινης και οι χρησεις τους ως αναστολεις γλυκοζυλοκεραμιδασης | |
| JP2011500713A5 (https=) | ||
| JP2015530389A5 (https=) | ||
| JP2016512230A5 (https=) | ||
| TWI641374B (zh) | 含低用量伊立替康鹽酸鹽水合物之抗腫瘤劑 | |
| JP2010270124A5 (https=) | ||
| RU2016148887A (ru) | Пиридиновые соединения пладиенолида и способы применения | |
| CY1108324T1 (el) | Νεοι τεταρτοταγοποιημενοι εστερες κουινουκλιδινης | |
| JP2013504582A5 (https=) | ||
| JP2019535760A5 (ja) | ガボキサドールを用いた注意欠陥多動性障害（ａｄｈｄ）の治療方法 | |
| JOP20220281A1 (ar) | مركبات وتركيبات لتثبيط نشاط hif2 ألفا وطرق لاستخدامها | |
| JP2017533220A5 (https=) | ||
| MX2024006074A (es) | Inhibidor de parp1 selectivo y aplicacion del mismo. | |
| JP2018522028A5 (https=) | ||
| JP2016517401A5 (https=) | ||
| Selvaggi et al. | Wingless/It/β-catenin signaling in liver metastasis from colorectal cancer: A focus on biological mechanisms and therapeutic opportunities | |
| JP2012522842A5 (https=) | ||
| JP2015507020A5 (https=) | ||
| JP2018527360A5 (https=) | ||
| JP2021505669A5 (https=) | ||
| JP2022516054A5 (https=) |